Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:58:09.603Z.
Calculation as of: 2026-10-06T17:58:09.603Z.
Quote observation: 2026-10-06T17:55:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$840.85M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$844.84M
Price/FCF Ratio
N/A
TTM Avg
198.42
3Y Avg
198.42
5Y Avg
198.42
Market Cap
$836.35M
Price/FCF Ratio
N/A
TTM Avg
12.01
3Y Avg
12.01
5Y Avg
12.01
Market Cap
$849.66M
Price/FCF Ratio
N/A
TTM Avg
104.86
3Y Avg
47.92
5Y Avg
28.61
Market Cap
$860.37M
Price/FCF Ratio
10.84
TTM Avg
9.59
3Y Avg
14.15
5Y Avg
25.73
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $840.85M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $839.06M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $844.84M | N/A | 198.42 | 198.42 | 198.42 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $836.35M | N/A | 12.01 | 12.01 | 12.01 |
| Alumis Inc. (ALMS)vs › | $833.76M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $849.66M | N/A | 104.86 | 47.92 | 28.61 |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | N/A | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $860.28M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.37M | 10.84 | 9.59 | 14.15 | 25.73 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $866.88M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
